Excision BioTherapeutics Stock

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Sign up today and learn more about Excision BioTherapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Excision BioTherapeutics Stock

Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Funding History

September 2017$10.0M
December 2019$750K
February 2021$60.0M


Board Member

Vasudev Bailey

Board Member

Ashok Krishnamurthi


Daniel Dombusch


Neal Kaplan

Interim Chief Business Officer

Michael Aberman

Principal Scientific Advisor

Khamel Khalili


Rob Simmons


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: